Quoin Pharmaceuticals (NASDAQ:QNRX) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Quoin Pharmaceuticals (NASDAQ:QNRX) released its quarterly earnings data on Thursday. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.15, Zacks reports.

Quoin Pharmaceuticals Trading Up 2.0 %

Shares of NASDAQ QNRX opened at $0.30 on Thursday. The stock has a market capitalization of $1.53 million, a PE ratio of -0.07 and a beta of 1.82. Quoin Pharmaceuticals has a 12-month low of $0.27 and a 12-month high of $1.57. The stock’s fifty day simple moving average is $0.41 and its two-hundred day simple moving average is $0.56.

Insiders Place Their Bets

In other Quoin Pharmaceuticals news, CFO Gordon Dunn purchased 122,221 shares of Quoin Pharmaceuticals stock in a transaction on Monday, December 23rd. The stock was bought at an average cost of $0.45 per share, with a total value of $54,999.45. Following the transaction, the chief financial officer now owns 151,077 shares of the company’s stock, valued at $67,984.65. This represents a 423.55 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Anthony James Culverwell acquired 100,000 shares of the company’s stock in a transaction dated Monday, December 23rd. The stock was acquired at an average cost of $0.45 per share, for a total transaction of $45,000.00. Following the completion of the acquisition, the director now directly owns 100,317 shares in the company, valued at approximately $45,142.65. The trade was a 31,545.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 777,777 shares of company stock worth $350,000. 3.70% of the stock is owned by corporate insiders.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.